| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Nurix Therapeutics, Inc. | Director, 10%+ Owner | Director Stock Option (right to buy) | 17,500 | 06 May 2021 | Direct | ||
| Septerna, Inc. | Director | Stock Option (Right to Buy) | 16,623 | 17 Jun 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| SEPN | Septerna, Inc. | 17 Jun 2025 | 1 | $0 | 4 | Director | 20 Jun 2025, 18:42 |
| MAZE | Maze Therapeutics, Inc. | 30 Jan 2025 | 0 | $0 | 3 | Director | 30 Jan 2025, 16:39 |
| SEPN | Septerna, Inc. | 24 Oct 2024 | 0 | $0 | 3 | Director | 24 Oct 2024, 21:34 |
| RAPP | Rapport Therapeutics, Inc. | 06 Jun 2024 | 0 | $0 | 3 | Director | 06 Jun 2024, 19:06 |
| NRIX | Nurix Therapeutics, Inc. | 06 May 2021 | 1 | $0 | 4 | Director, 10%+ Owner | 24 May 2021, 19:50 |